BSV-HUMOG

Indications

• Female infertility
• Ovarian stimulation in assisted reproductive technology
• Hypogonadotropic hypogonadism in males

Dosage

Children: Not applicable, as menotropin is not indicated for paediatric use.

Adults: Refer to specific guidelines for dosing, as it varies based on the indication and patient response.

Mechanism of action

Menotropin exerts its effects by binding to the FSH and LH receptors on ovarian follicles. This binding activates signaling pathways that promote follicular development and ovulation. The presence of both FSH and LH in menotropin is necessary for the stimulation of the ovaries, leading to increased estrogen production and maturation of the oocytes.

Pharmacodynamics

The pharmacodynamic effects of menotropin include the stimulation of ovarian follicle growth and maturation, which is essential for ovulation. In women, the administration of menotropin increases serum estradiol levels, leading to the development of multiple follicles. In men, it can help in the stimulation of spermatogenesis by acting on Leydig cells and Sertoli cells.

Pharmacokinetics

Menotropin is administered via subcutaneous or intramuscular injection. It has a bioavailability that is not fully characterized due to its protein nature. The elimination half-life of menotropin is variable and depends on the dose and individual patient factors. It is metabolized by the liver and excreted in urine. The pharmacokinetics may be influenced by the presence of other medications, overall health, and hormonal status.

Contra-indications

• Hypersensitivity to menotropins or any of the excipients
• Pregnancy
• Ovarian cysts or enlarged ovaries not due to polycystic ovary syndrome
• Primary ovarian insufficiency
• Uncontrolled thyroid or adrenal dysfunction
• Tumors of the pituitary gland or hypothalamus
• Sex hormone-dependent tumors

Adverse effects

• Ovarian hyperstimulation syndrome (OHSS)
• Multiple pregnancies
• Abdominal pain
• Nausea
• Headache
• Injection site reactions
• Breast tenderness
• Mood changes

Interactions

• Caution with other hormonal therapies due to risk of OHSS
• Concurrent use with GnRH analogs may require dose adjustments

Precautions

• Monitor for signs of OHSS during treatment
• Evaluate ovarian response to stimulation
• Consider patient’s medical history and current medications
• Use with caution in patients with a history of thromboembolic disorders

Pregnancy

Menotropins are contraindicated during pregnancy due to potential risks to the fetus.

Breast-feeding

It is unknown whether menotropins are excreted in human milk. Caution is advised.

Storage

Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light.

Formulations

• Injection solution